Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Meropenem

Classification: A

Drug products: Meronem, Meronem®, Meropenem Bradex, Meropenem FarmaPlus, Meropenem Fresenius Kabi, Meropenem Hexal, Meropenem Mylan, Meropenem Pfizer, Meropenem Sandoz, Meropenem STADA, Meropenem-Rotexmedica

ATC code: J01DH02

Substances: meropenem, meropenem trihydrate

Summary

Studies have shown that the response to meropenem is similar in men and women.
 
In our opinion, the described differences do not motivate differentiated dosing or treatment in men and women.

Additional information

Pharmacokinetics and dosing

A population pharmacokinetic model of meropenem in Japanese adult patients with febrile neutropenia has been developed with patient data from an open-label Phase 3 clinical study (64 men, 34 women). Patients received meropenem 1 g every 8 h for 7-14 days. The volume of distribution was higher in men (13.8 vs. 10.7 L). However, Cmax, Tmax and plasma concentration levels were similar in men and women, despite renal function [2].

Effect

In a randomized double-blind trial conducted by the manufacturer, adult patients (in total 1037) with complicated skin and skin structure infections received 500 mg meropenem i.v. every 8 h or 500 mg imipenem-cilastatin IV every 8 h. Percent of patients with satisfactory clinical response at the follow-up visit were similar in men and women receiving meropenem (88% and 84%, respectively) [3].

Meropenem (1 g every 8 h) were compared to doripenem (500 mg every 8 h) in a phase 3, randomized, double-blind study including hospitalized adult patients (200 men, 119 women) with complicated intra-abdominal infections. The clinical cure rates were similar in men and women receiving meropenem (85.1% and 85.5%, respectively) [4]. The clinical and bacteriological responses to ceftazidime (1 g every 8 h) versus meropenem (0.5 g every 8 h) were assessed in hospitalized patients (257 men, 152 women) with community-acquired pneumonia, according to risk factors. The responses were similar in men and women in both treatment groups [1].

Adverse effects

No studies with a clinically relevant sex analysis regarding adverse effects of meropenem have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).

Updated: 2019-02-26

Date of litterature search: 2016-08-17

References

  1. Finch RG, Pemberton K, Gildon KM. Pneumonia: the impact of risk factors on the outcome of treatment with meropenem and ceftazidime. J Chemother. 1998;10:35-46. PubMed
  2. Ohata Y, Tomita Y, Nakayama M, Tamura K, Tanigawara Y. Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic-pharmacodynamic analysis. J Infect Chemother. 2011;17:831-41. PubMed
  3. Merrem IV (meropenem). DailyMed [www]. US National Library of Medicine. [updated 2016-07-27, cited 2016-08-17]. länk
  4. Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther. 2008;30:868-83. PubMed
  5. Concise. Stockholm: eHälsomyndigheten. 2015 [cited 2016-08-22.] länk

Authors: Linnéa Karlsson Lind

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson